Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides

10 Mar 2016

Abstract excerpt

The growing problem of antimicrobial resistance among bacterial pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), has reached a critical state. Tedizolid phosphate, dalbavancin, and oritavancin have recently been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal resistance and susceptibility
Share to Antimicrobial Resistance in Staphylococcus
Share to Carbohydrate Chemistry and Synthesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26962092
DOI: 10.1128/jcm.03395-15

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New Gram-Positive Agents: the Next Generation of Oxazolidinones and LipoglycopeptidesPMID 26962092Read ↗

Surveillance of tedizolid activity and resistance: In vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and EuropeSemantic proximity Read ↗

Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.Semantic proximity Read ↗

Tedizolid for the Management of Human Infections: In Vitro CharacteristicsSemantic proximity Read ↗

From Vancomycin to Oritavancin: The Discovery and Development of a Novel Lipoglycopeptide AntibioticSemantic proximity Read ↗

The oxazolidinones: past, present, and future.Semantic proximity Read ↗

Comparativein vitroactivity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococciSemantic proximity Read ↗

Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.Semantic proximity Read ↗

Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensSemantic proximity Read ↗

Oxazolidinones: activity, mode of action, and mechanism of resistance.Semantic proximity Read ↗

Thrombocytopenia and Tedizolid: A new ally in hematologic patients? Brief literature review and a clinical caseSemantic proximity Read ↗

Effect of tedizolid on clinical Enterococcus isolates: in vitro activity, distribution of virulence factor, resistance genes and multilocus sequence typingSemantic proximity Read ↗

Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013–2014)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.